396 results about "Immune reaction" patented technology

The invention relates to the technical field of bioengineering, in particular to a recombinant VII type collagen for inhibiting scars as well as a preparation method and application of the recombinant VII type collagen. The amino acid sequence of the recombinant VII type collagen is as shown in SEQ ID NO. 1. The recombinant VII type collagen provided by the invention has a better cell adhesion function, so that the recombinant VII type collagen can be applied to the fields of preparation of tissue materials, wound dressings and the like. Meanwhile, the VII type collagen does not contain any tag or exogenous amino acid sequence, is a completely humanized sequence, and does not generate immune response. The VII type collagen has a good adhesion effect, the adhesion effect is better than that of other recombinant collagen, the adhesion effect is equivalent to that of a common cell adhesive in the market, scars can be reduced by inhibiting activation of a TGF-beta pathway, and the VII type collagen can be developed into skin care products and medical instruments for promoting traceless wound repair and has a wide application prospect.

The invention provides an immunodetection method of a multi-index immune checkpoint detection kit, which belongs to the technical field of immunodetection and comprises three main stages of sample preparation, immune reaction and data analysis. The method comprises the following steps: firstly, carrying out centrifugal separation to obtain a plasma sample, and preparing a fluorescent microsphere coupled capture antibody and biotin labeled detection antibody compound; then carrying out immune reaction, forming a sandwich type immune complex through specific binding, and adding streptavidin marked by phycoerythrin for signal amplification. Detecting a fluorescence signal by adopting a flow cytometer to obtain an original data matrix; a contribution feature vector, a utility feature vector and an expression feature matrix are extracted through a feature decomposition algorithm, and a deep learning model of a total-score-total structure is established for data analysis. Finally, a detection report containing a quantitative result, an importance score and reliability evaluation is generated, and the technical problem that in the prior art, the analysis accuracy of a multi-index immune checkpoint detection result is insufficient is solved.

The invention discloses a YOLO-Drop-based 3D printing droplet microfluidic immunoassay method, which organically integrates a high-precision microfluidic chip preparation technology, a droplet-level immunoreaction system and a fluorescence imaging acquisition and deep learning detection algorithm. And full-chain closed-loop processing from droplet generation, fluorescence signal acquisition, image recognition, result statistics to concentration quantitative analysis is realized. Through deep combination of chip physical parameters and model input features, the method not only significantly improves the accuracy and stability of droplet identification and concentration quantification, but also enhances the robustness of the algorithm under complex sample conditions through multi-scale feature fusion and a signal dual screening mechanism. Meanwhile, the optimized YOLO-Drop model supports embedded efficient reasoning, so that the whole analysis process has the characteristics of real-time performance and high throughput, and the method is suitable for rapid quantitative detection of various biomarkers.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.

The invention relates to the technical field of veterinary epidemic disease detection, and discloses a veterinary epidemic disease remote monitoring and intelligent diagnosis system, which comprises a multi-mode biosensor array including an implantable miniature biochip, a wearable flexible physiological monitoring patch and an environment sensing sensor cluster, the implantable miniature biochip is used for being implanted into a key tissue organ area in an animal body and collecting microscopic physiological data such as cellular metabolism signals and local immune reaction marker concentration in real time, and the wearable flexible physiological monitoring patch is used for being attached to the body surface of the animal. By means of the multi-mode biosensor array and the edge intelligent preprocessing unit, animal physiology and environment data are accurately monitored in real time. The multi-modal biosensor array covers the implantable miniature biochip, the wearable flexible physiological monitoring patch and the environment sensing sensor cluster, and can comprehensively collect in-vivo microscopic physiological data, body surface macroscopic physiological parameters and feeding environment information of animals.

The invention relates to the technical field of medicinal chemistry, and provides a TLR4 agonist, application thereof and a vaccine composition. The TLR4 agonist is a compound with a structure as shown in a formula 1 or a pharmaceutically acceptable salt thereof, the compound is glucosamine aminoalkyl 4-phosphate series molecules derived from MPL-12 structure modification, and the series molecules have enhanced immunostimulatory activity and selective immune response induction capability.

The invention belongs to the technical field of anti-tumor, and discloses application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA. The excellent drug delivery capacity of the hydrogel system is utilized, and the in-vivo local slow release effect of ICT and BMS202 can be remarkably amplified. Through synergistic treatment of the TAN and the MDSC, local and whole body adaptive immunoreactions can be efficiently activated, TAN is effectively reprogrammed to be in a tumor suppression type, infiltration of PMN-MDSC is reduced, and the conclusion is verified in a plurality of mouse tumor models in the chapter. Therefore, the HP (at) ICT / BMS provides a promising delivery strategy for improving the sensitivity of anti-PD-L1 treatment and efficiently preventing and treating latent residual cancer and metastasis after IRFA operation.

The invention discloses a 3D printing bone grafting window-free porous tantalum metal interbody fusion cage which comprises a fusion cage body, the fusion cage body is integrally formed by machining medical-grade tantalum metal, and a clamping hole is formed in the front side of the fusion cage body and used for being connected with an operation instrument; the two groups of porous net racks are respectively fixed on the upper surface and the lower surface of the fusion cage body, the outer side surface of each porous net rack is a contact interface, and each contact interface is of an arc-shaped structure; bayonets are symmetrically formed in the inner wall of the front side of the fusion cage body, the clamping hole is formed between the bayonets, and the bayonets are used for limiting operation instruments. The porous tantalum material with high biological activity and high porosity is adopted, reliable spinal fusion can be achieved on the premise that bone grafting is not needed, the problems of bone taking trauma and donor region complications related to bone grafting and immunoreaction caused by allogeneic bone grafting are effectively solved, and therefore the occurrence risk of postoperative complications is reduced, and the bone grafting success rate is increased. The postoperative recovery process of the patient is improved.

The invention discloses a carbamate compound, lipid nanoparticles constructed by the carbamate compound, a pharmaceutical composition and application of the carbamate compound. A lipid nanoparticle carrier constructed by the series of cationic amino lipid compounds (formula I) can deliver mRNA to the spleen in a targeted manner on the premise of ensuring high efficiency and low toxicity, so that the immune response is effectively stimulated, the curative effect is remarkably improved, and the cationic amino lipid compound has important clinical application significance in cancer treatment.

Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

The invention relates to an active oxygen concentration control method and a brain-computer interface implant accelerated life test system. The accelerated life test system is used for testing the electrochemical performance of a brain-computer interface implant by using a test solution. The method comprises the following steps: detecting a current feedback current corresponding to a current test solution; obtaining the current active oxygen concentration according to the current feedback current and a preset active oxygen concentration and current relation function; generating a filling parameter according to a concentration difference value between the current active oxygen concentration and a preset active oxygen concentration; and adding a hydrogen peroxide solution into the current test solution according to the filling parameters, so that the current test solution reaches the preset active oxygen concentration. According to the method, the active oxygen environment generated by immune reaction in a living body can be simulated through the test solution, the active oxygen concentration in the test solution can be precisely regulated and controlled, and the accuracy of the test result of the brain-computer interface implant is improved.

The invention belongs to the field of medicines, and particularly relates to a nanosheet capable of activating an STING pathway and improving microwave ablation as well as a preparation method and application of the nanosheet. The nanosheet is prepared from MXenes through organic acid treatment, organic alkali dispersion, STING agonist compounding and phospholipid modification, and has good microwave thermal conversion efficiency and an STING pathway activation function. The combined microwave ablation can enhance the immunogenic death of tumor cells, promote the maturation of dendritic cells, doubly activate immune response and effectively inhibit the growth and metastasis of prostatic cancer, provides a new strategy for the treatment of prostatic cancer, and can be used for preparing drugs for treating prostatic cancer.

The application discloses a kiwi bacterial canker disease susceptible gene AcADC1 and application thereof, and belongs to the technical field of genetic engineering. The nucleotide sequence of the AcADC1 gene is shown in SEQ ID NO:1, and the arginine decarboxylase (ADC) synthesized by the gene is encoded, and the amino acid sequence is shown in SEQ ID NO:2, and the arginine (Arg) is responsible for catalyzing the formation of putrescine. The resistance of the kiwi plant with the silenced AcADC1 gene to the bacterial canker disease is improved, the resistance of the kiwi plant with the overexpressed AcADC1 gene to the bacterial canker disease is reduced, the AcADC1 gene plays a negative regulation role in the immune response of the kiwi to the bacterial canker disease, the gene editing technology can be used for editing the AcADC1 gene, and a theoretical basis and gene reserve are provided for kiwi disease-resistant breeding.

The present invention includes novel compositions and methods for treating comprising a compound with the Formula I:wherein n=0, 1, 2, 3, 4, or 5; X=NH or O or S; Y=phenyl, or a phenyl group substituted with at least one methyl, a phenyl group substituted with at least one nitro, a phenyl group substituted with at least one nitrogen, a phenyl group substituted with at least one boron, aryl, substituted aryl, heteroaryl, four to six membered cycloalkyl, four to six membered heterocycloalkyl; R=H, C(O)R2, SO2R2; R1=H, C(O)R2, SO2R2; R2=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH2, NR3R4; R3, R4=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl, and Z=NH, or O, or none, and optionally wherein both X and Z are not both S, and wherein the amount of the compound is selected to either inhibit or activate the immune response.

The invention provides an influenza virus that demonstrates enhanced growth in Vero cells. The influenza virus includes PA, NP, and NS gene segments having selected nucleotides and encoding proteins having amino acid sequences with selected amino acids. The invention also provides a pharmaceutical formulation containing the influenza virus, as well as a method of eliciting an immune response in a mammal by administering the influenza virus to the mammal, and a method for generating the influenza virus.

The invention provides a herpes simplex virus mRNA vaccine as well as a preparation method and application thereof. According to the present invention, through a series of selection and optimization, the antigen protein suitable for preparing the mRNA vaccine, especially the combination of gD2 and gE1, is obtained, and the divalent vaccine prepared based on the antigen protein has excellent effect. The novel mRNA vaccine disclosed by the invention can efficiently induce humoral immune response, cellular immune response and T cell immune response, so that the novel mRNA vaccine can be effectively used for preventing and controlling herpes simplex virus infection, and can simultaneously cover the prevention and control of two viruses, namely HSV-1 and HSV-2.

Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

The invention belongs to the technical field of biological medicine, and particularly relates to a nano vaccine based on GD2 mimetic peptide as well as a preparation method and application of the nano vaccine. The nano vaccine provided by the invention comprises a GD2 mimetic peptide, an STING agonist and a polymer carrier, wherein the STING agonist is used as an immunologic adjuvant. The antigen peptide (GD2 mimic peptide 47-LDA) and the adjuvant (STING agonist) are wrapped in the micelle to prepare the nano vaccine GD2-NV, so that the druggability of the antigen peptide and the STING agonist is improved, and the accumulation of drug tumors and drainage lymph node parts is improved. Besides, the nano vaccine can respond to a lysosome acid environment, realize lysosome escape, enhance antigen cross presentation of DC, activate an STING pathway, improve infiltration and activation degrees of CD8 + T cells, induce lasting humoral immune response and inhibit growth and recurrence of tumors, and is good in biological safety.

Compositions and methods of use for modulating APOE mediated signaling are provided. For example, immunomodulatory agents are provided that reduce APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. In another embodiment, immunomodulatory agents are provided that enhance or promote APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. Such agents can be used to modulate an immune response in a subject in need thereof, wherein the subject has a neurodegenerative disease, such as Alzheimer's disease or cerebral amyloid angiopathy.

Provided herein are methods and compositions for the detection of Brucella antigen, and more particularly, to a vaccine or immunogenic composition comprising: Brucella strain from which at least a portion of the immunogenic protein DUF883 has been deleted provided in an amount sufficient to trigger an immune response against the immunogenic protein; and a pharmaceutically acceptable vaccine carrier.

This invention relates to a self-adjuvanted biomimetic lipid nanoparticle, its microfluidic assembly method, and its anti-tumor applications. The self-adjuvanted biomimetic lipid nanoparticle has a structure in which an activated dendritic cell membrane (ADCM) is coated on the surface of a lipid nanoparticle (LNP) loaded with mRNA. The advancements of this invention compared to traditional LNPs are: the self-adjuvanted biomimetic lipid nanoparticle (ADCM-LNP) exhibits a faster cellular uptake rate and higher transfection efficiency, thereby inducing a strong Th1-type immune response and a potent CTL-mediated tumor-killing effect. In vivo biodistribution studies have shown that this system exhibits significant spleen-targeting (splenic tropism) and demonstrates excellent therapeutic efficacy in a HER2-positive breast cancer model.

A method, device and computer readable medium for identifying hook effect in immunoturbidimetry. The method generates a reaction curve by measuring optical signals of an immune reaction of a to-be-measured substance in a sample within a predetermined time period, and determines whether the sample has hook effect by using distribution information of the reaction curve within the predetermined time period. The method only uses measurement information of a small predetermined time period in the entire reaction time to identify samples with hook effect, and terminates the detection in time, thereby accelerating the speed of immunoturbidimetry detection of samples with hook effect.

AAV vectors are ideally suited for long-term delivery of a combination of broadly neutralizing antibodies to achieve sterilizing immunity to HIV. Unfortunately, host immune responses to the delivered antibody have severely limited the efficacy. The TLR9 pathway has been identified in initiating adaptive immune responses against AAV and delivered bNAbs. To enhance this strategy, we validated Hydroxychloroquine, a known drug inhibitor of the TLR9 pathway, as a pretreatment to AAV delivery to avoid anti-drug antibody responses. TLR9 signaling inhibition was validated using a HEK-Blue hTLR9 reporter cell line and CpG stimulation. Hydroxychloroquine was also validated in a 3-macaque trial where AAV9-3BNC117 and AAV9-10-1074 were administered along with 3 doses of hydroxychloroquine once a week starting 1 week before AAV inoculation. Unlike historical controls, where 3BNC117 and 10-1074 expression is lost within the first 4-5 weeks, 2 macaques maintained 10-1074 expression and 1 macaque maintained 3BNC117 for the duration of the trial. Anti-3BNC117 antibodies were only observed in 2 of the 3 macaques and were significantly delayed. Anti-10-1074 antibody responses were a log lower than typically observed in historic controls. The use of hydroxychloroquine as a pretreatment for AAV inoculation is a promising strategy. The significant decrease in anti-10-1074 antibody levels and the successful delivery of 10-1074 in 2 macaques and 3BNC117 in 1 macaque was very encouraging. Extending the dosage of hydroxychloroquine beyond 3 doses may be sufficient to observe long-term bNAb expression in all animals and further decrease ADA responses. Together, these data suggest that the short-term treatment of hydroxychloroquine at the time of AAV inoculation has a meaningful impact on tolerance induction to our AAV-delivered bNAbs.

The use of anti-HPV immunogens and nucleic acid molecules encoding them for the treatment and prevention of RRP is disclosed.SOLUTION: Pharmaceutical compositions, recombinant vaccines comprising the DNA plasmids, and live attenuated vaccines are disclosed, as well as methods of inducing an immune response to treat or prevent RRP.SELECTED DRAWING: Figure 1

Systems and methods for the detection of sepsis and treatment of patients. A sepsis detection system includes a first subsystem configured to detect the presence of an infection in a patient, a second subsystem configured to detect the presence of a dysregulated immune response in the patient, a third subsystem configured to detect organ dysfunction in the patient, a fourth subsystem configured to detect antibiotic resistance (ARB) of a pathogen in the patient, and a processing device. The first, second, third, and fourth subsystems and the processing device are communicatively coupled to each other via a network. The processing device is configured to determine the presence of sepsis in the patient based on the presence of infection, the presence of the dysregulated host response, and clinical data indicative of organ dysfunction in the patient.The subsystems utilize at least one polymerase chain reaction (PCR) procedure, Raman spectroscopy, clinical data, electronic health record (EHR) data, and antibiotic susceptibility testing (antibiogram).

The invention relates to the technical field of biomedical detection, in particular to an inflammatory bowel disease recurrence early warning method and system based on excrement calprotectin, and the method comprises the following steps: collecting three excrement samples of the same defecation event, splitting and extracting, carrying out immunodetection under different dilution rates to obtain point concentration, and calculating the concentration of the excrement calprotectin; forming an observation data packet containing a dilution consistency index, immunoreaction kinetics uncertainty and spatial heterogeneity uncertainty; synthesizing a measurement variance, calculating an observation gain, updating an inflammatory activity hidden state, and generating a trend slope, an accumulated offset and an individual dynamic threshold value; generating an event code according to the state data to trigger anti-certification retest so as to output an anti-certification result and a detection design instruction; and recursively accumulating evidences based on the state and the anti-evidence result, outputting low / medium / high risk early warning according to the boundary, and updating individual parameters after obtaining a recurrence outcome label. According to the method, the early warning stability and interpretability are improved, false alarm and missing alarm are reduced, and the retest cost is optimized.